Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Post-transplant lymphoproliferative disorders.

Ann S LaCasce1

  • 1Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. Ann_LaCasce@dcfi.harvard.edu

The Oncologist
|June 24, 2006
PubMed
Summary

Post-transplant lymphoproliferative disorder (PTLD) is a common malignancy after organ transplants, often linked to Epstein-Barr virus. Its variable prognosis stems from diverse disease presentations, from hyperplasia to aggressive forms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL.

Blood advances·2026
Same author

Rethinking Cardiovascular Events, End Points, and Surveillance in Oncology Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade.

Blood neoplasia·2025
Same author

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.

Blood advances·2025
Same author

A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.

Blood advances·2025
Same author

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2025

Area of Science:

  • Oncology
  • Transplantation Immunology
  • Virology

Background:

  • Post-transplant lymphoproliferative disorder (PTLD) is a significant clinical challenge following solid organ transplantation.
  • PTLD represents the most frequent malignancy, excluding skin cancer, in adult transplant recipients.
  • The incidence and clinical presentation of PTLD are influenced by the type of transplanted organ and Epstein-Barr virus (EBV) status.

Purpose of the Study:

  • To summarize the key aspects of post-transplant lymphoproliferative disorder.
  • To highlight the association between PTLD and Epstein-Barr virus.
  • To underscore the variable prognosis due to disease heterogeneity.

Main Methods:

  • Review of existing literature on PTLD.
  • Analysis of incidence rates based on organ type.
  • Examination of the role of Epstein-Barr virus in PTLD pathogenesis.

Main Results:

  • PTLD is a common complication after solid organ transplantation.
  • Epstein-Barr virus is frequently implicated in the development of PTLD.
  • Disease spectrum ranges from benign hyperplasia to aggressive lymphoma, impacting prognosis.

Conclusions:

  • PTLD management requires consideration of its varied clinical and pathological spectrum.
  • Understanding the EBV association is crucial for PTLD diagnosis and treatment.
  • Prognosis in PTLD is highly variable and dependent on disease subtype and host factors.

Related Experiment Videos